Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2023-03-15 00:00:00 ET · period of report 2023-03-14 · accession 0001209191-23-018952 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-15 | 2023-03-14 | ORMP | Kidron Miriam | CSO, Dir | S - Sale | $2.01 | -100.0K | 201.7K | -33% | -$201.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-14 | S | D | 100,000 | $2.01 | 201,666 | D | — | — | (F1) These shares were sold to a company owned solely by Nadav Kidron, a director and the president and chief executive officer of the Issuer, and the Reporting Person used the proceeds in connection with a personal tax payment. |